Luke Sergott
Stock Analyst at Barclays
(2.18)
# 2,514
Out of 5,182 analysts
403
Total ratings
38.05%
Success rate
-3.39%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Maintains: Underweight | $110 → $122 | $135.78 | -10.15% | 23 | May 1, 2026 | |
| QGEN Qiagen | Maintains: Equal-Weight | $44 → $38 | $34.25 | +10.95% | 5 | Apr 29, 2026 | |
| WST West Pharmaceutical Services | Maintains: Equal-Weight | $275 → $310 | $300.68 | +3.10% | 7 | Apr 27, 2026 | |
| MEDP Medpace Holdings | Maintains: Equal-Weight | $500 → $450 | $417.54 | +7.77% | 8 | Apr 24, 2026 | |
| DGX Quest Diagnostics | Maintains: Overweight | $225 → $230 | $192.67 | +19.38% | 1 | Apr 22, 2026 | |
| BRKR Bruker | Maintains: Overweight | $50 → $45 | $36.79 | +22.32% | 11 | Apr 15, 2026 | |
| AVTR Avantor | Maintains: Underweight | $8.5 → $7 | $7.96 | -12.06% | 30 | Apr 15, 2026 | |
| TXG 10x Genomics | Maintains: Overweight | $22 → $30 | $22.43 | +33.75% | 16 | Apr 14, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $150 → $140 | $114.52 | +22.25% | 16 | Apr 14, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $200 → $210 | $165.78 | +26.67% | 13 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $230 | $175.15 | +31.32% | 42 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $12.18 | -9.69% | 16 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $130 → $115 | $87.60 | +31.28% | 7 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,550 → $1,500 | $1,267.07 | +18.38% | 5 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $1.60 | -37.50% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $145 | $117.20 | +23.72% | 6 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $18 | $15.50 | +16.13% | 24 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $625 | $469.21 | +33.20% | 31 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $60.40 | -8.94% | 22 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $118 → $95 | $86.68 | +9.60% | 14 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $200 → $120 | $112.85 | +6.34% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $210 | $157.77 | +33.11% | 26 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $8 | $6.18 | +29.45% | 22 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $400 | $307.12 | +30.24% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $207.28 | +30.26% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $96.91 | -7.13% | 1 | Aug 1, 2025 |
Illumina
May 1, 2026
Maintains: Underweight
Price Target: $110 → $122
Current: $135.78
Upside: -10.15%
Qiagen
Apr 29, 2026
Maintains: Equal-Weight
Price Target: $44 → $38
Current: $34.25
Upside: +10.95%
West Pharmaceutical Services
Apr 27, 2026
Maintains: Equal-Weight
Price Target: $275 → $310
Current: $300.68
Upside: +3.10%
Medpace Holdings
Apr 24, 2026
Maintains: Equal-Weight
Price Target: $500 → $450
Current: $417.54
Upside: +7.77%
Quest Diagnostics
Apr 22, 2026
Maintains: Overweight
Price Target: $225 → $230
Current: $192.67
Upside: +19.38%
Bruker
Apr 15, 2026
Maintains: Overweight
Price Target: $50 → $45
Current: $36.79
Upside: +22.32%
Avantor
Apr 15, 2026
Maintains: Underweight
Price Target: $8.5 → $7
Current: $7.96
Upside: -12.06%
10x Genomics
Apr 14, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $22.43
Upside: +33.75%
Agilent Technologies
Apr 14, 2026
Maintains: Overweight
Price Target: $150 → $140
Current: $114.52
Upside: +22.25%
Charles River Laboratories International
Apr 14, 2026
Maintains: Overweight
Price Target: $200 → $210
Current: $165.78
Upside: +26.67%
Apr 14, 2026
Maintains: Overweight
Price Target: $250 → $230
Current: $175.15
Upside: +31.32%
Apr 14, 2026
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $12.18
Upside: -9.69%
Apr 14, 2026
Maintains: Overweight
Price Target: $130 → $115
Current: $87.60
Upside: +31.28%
Apr 14, 2026
Maintains: Overweight
Price Target: $1,550 → $1,500
Current: $1,267.07
Upside: +18.38%
Apr 14, 2026
Maintains: Underweight
Price Target: $1.5 → $1
Current: $1.60
Upside: -37.50%
Apr 14, 2026
Maintains: Overweight
Price Target: $175 → $145
Current: $117.20
Upside: +23.72%
Apr 14, 2026
Maintains: Overweight
Price Target: $20 → $18
Current: $15.50
Upside: +16.13%
Apr 14, 2026
Maintains: Overweight
Price Target: $650 → $625
Current: $469.21
Upside: +33.20%
Apr 14, 2026
Maintains: Overweight
Price Target: $50 → $55
Current: $60.40
Upside: -8.94%
Apr 14, 2026
Downgrades: Equal-Weight
Price Target: $118 → $95
Current: $86.68
Upside: +9.60%
Mar 9, 2026
Maintains: Equal-Weight
Price Target: $200 → $120
Current: $112.85
Upside: +6.34%
Mar 6, 2026
Upgrades: Overweight
Price Target: $210
Current: $157.77
Upside: +33.11%
Mar 6, 2026
Downgrades: Equal-Weight
Price Target: $8
Current: $6.18
Upside: +29.45%
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $307.12
Upside: +30.24%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $207.28
Upside: +30.26%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $96.91
Upside: -7.13%